We are a team of scientists, clinicians, and engineers.
Bobby left Illumina to pursue Pathway Bio, inspired by his friend who lost her life to cancer, the grit he saw in other founders to change the world and people with cancer to address the way in which we treat cancer patients. Previously, Bobby headed up Global Entrepreneurial & Ecosystem Development at illumina, developing models that will accelerate the creation of genomics and VC backable startups. He co-created Illumina for Startups and co-launched Illumina accelerator UK. Prior to this, he was Head, Market and Business Development Illumina EMEA, leveraging next generation technologies to drive next generation therapeutics and diagnostics. His interest has always been at the intersect of patients, technology and science, having the privilege of spending some time in the NHS and several years at Roche, in various roles. His background is Neuroscience, Genetics, IT.
He continues to support the startup ecosystem, through his engagements at universities, co-chair of SBRI and lending his experience to those trying to make a change.
Kimberly Robasky, PhD, is co-founder and VP of AI & Data Engineering at Pathway Bio. With 20+ years of experience across startups, academia, and industry, she has built and led teams developing AI-powered data platforms, multi-omic pipelines, and predictive models that support NIH initiatives and drug discovery. Widely published with nearly 2,000 citations, she focuses on turning complex data into actionable insights that accelerate therapies and improve patient outcomes.
Professor of Cancer Biology, Mayo Clinic
Co-Director, Cancer Genomics, Signaling, and Metastasis Program
Mayo Clinic Comprehensive Cancer Center
Panos is a cancer biologist whose research explores how cell adhesion signalling events regulate tumor growth, invasion, and metastasis. By uncovering how these mechanisms become disrupted in cancer, his team aims to identify new ways of tackling cancer.
The Anastasiadis Lab also combines advanced cell biology with genomics, transcriptomics, proteomics, and bioinformatics to define oncogenic pathways in individual patient tumors. In collaboration with the Mayo Clinic Center for Individualized Medicine, the lab launched the Ex Vivo project, which tests therapies in patient-derived models across multiple cancer types to inform personalized treatment, and brings this technology to Pathway Bio.
Panos has extensive service on national NIH study sections, as chair of the Cancer Biology department at Mayo Clinic, and plays leadership roles within Mayo Clinic’s comprehensive cancer center.
Paul is an accomplished life sciences executive and non-executive director with over 30 years of global leadership experience, including more than 20 years in oncology and clinical diagnostics. He has held CEO and senior leadership roles at companies such as Diadem, PredictImmune, Transgenomic (NASDAQ), ZyGEM, Life Technologies (now Thermo Fisher), Guava Technologies, and Cellomics.
With a proven track record in commercialization, fundraising, M&A, and corporate strategy, Paul has raised more than £150m ($180m) across private and public markets, launched innovative products such as liquid biopsies, and built global partnerships that accelerated growth and shareholder value. Having spent over half of his career in the US, he brings a unique international perspective on healthcare markets.
Paul currently serves on multiple life sciences boards as a NED, where he mentors CEOs and guides companies in governance, commercialization, and strategic growth.
Tariq (MD FRCP FRCPath) completed his medical training in London UK and in Denver CO. He has made pioneering contributions to society, academic hematology and oncology, pharmaceutical medicine and cancer charity. He is internationally recognized as an expert in the development of targeted therapies and molecular diagnostics in cancer, particularly myeloid leukemias. Prior to joining Pathway Bio, Tariq was Senior Vice President and Head of Clinical Drug Development in Hematology at Stemline Therapeutics/Menarini, New York, NY, and previously served as Vice President Clinical/Medical Affairs at Foundation Medicine/Roche, Cambridge, MA. He is a Clinical Professor at Tufts University Medical School and founder of Alpine Oncology Foundation supporting efforts to advance the treatment of myeloid leukemias in Tanzania.
Tori completed her BA in Forensic Linguistics from Hofstra University, and joined Pathway Bio, to support our day-to-day operations. She supports the team in managing our tasks, organizing and documenting meetings and holding us to account on our deliverables. She has taken lead on our website design and identifying opportunities to raise funding from alternative sources.
